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“It’s going to hurt George,” she said, “but only for a moment.” 

Abstract
Propofol is today the most commonly used drug for induction of anaesthesia and for short-
term sedation. However, one specific problem is that intravenous injection of propofol 
often results in quite severe injection pain, which in the paediatric population is a serious 
clinical dilemma. Different methods have been tried in order to reduce injection pain, 
adding the local anaesthetic lidocaine being the most common, but the incidence of injec-
tion pain still remains 20-40%. Thus, there is an urgent need to find new alternatives to 
propofol that adequately will reduce injection pain during intravenous induction of anaes-
thesia.  Furthermore, there is on-going debate whether exposure to general anaesthesia in 
early life may be harmful since a large number of animal studies have shown various signs 
of neurotoxicity after anaesthesia exposure at an early age. New induction agents aimed 
for use also in neonates and infants must therefore be investigated with regards to potential 
neurotoxicity.  
In Study I the incidence and intensity of injection pain was compared between two dif-
ferent formulae of propofol; the former standard propofol solution (Diprivan®) with added 
lidocaine vs. a more novel plain formulation- Propofol-®Lipuro. Contrary to previous pub-
lished adult results, the new formula was associated with a higher incidence of injection 
pain compared to Diprivan®+ lidocaine (66.7 % vs 39.0 %) (P = 0.016). 
In Study II we compared Diprivan®+ lidocaine with an alternative hypnotic induction 
agent- etomidate- that now is available as a lipid preparation (Etomidate-®Lipuro). At an 
interim analysis demanded by the Ethics Committee, data showed that the pain incidence 
in the etomidate-group was significantly reduced compared to the propofol group (5.0 % 
vs 47.5 %; p < 0.001), and the study was subsequently stopped.
One of few side effects considering etomidate is a high incidence of myoclonic move-
ments (MM) following induction of anaesthesia. In adults the incidence and intensity of 
MM is reduced if a small, non-sedative priming dose of etomidate is administered imme-
diately before the main induction dose. 
The aim of Study III was to investigate if this therapeutic modification was valid also 
in children. However, no evidence for a reduced incidence of MM was found following 
the use of a small priming dose in children (incidence of MM: priming dose: 75.0 % vs. 
placebo: 72.5 %). A post hoc analysis did identify children in the age group 5-10 years to 
display a higher incidence of MM compared to other ages groups (P=0.0021). In study I-
III the incidence and severity of injection pain as well as the incidence and severity of MM 
were measured using 4-point assessment scores, which is in line with previously published 
paediatric studies.
In Study IV the effects on apoptosis and later behavioural alterations of varying doses 
of etomidate (0.3, 3, and 10 mg/kg) and two other commonly used anaesthetics (propofol 
60 mg/kg and ketamine 50 mg/kg) were studied in infant mice (postnatal day 10). No 
evidence of enhanced apoptosis was found in any of the treatment groups when compared 
to placebo. In contrast to the other groups, ketamine exposed mice expressed altered 
motor behaviour when tested at an age corresponding to young human adults (P< 0.01). 
Enhanced apoptosis was measured by activated caspase-3 (ELISA) and behavioural altera-
tions were assessed by measuring spontaneous activity in a new environment.
Conclusions
Etomidate-®Lipuro is associated with significantly less injection pain compared to tradi-
tional propofol (Diprivan®) with added lidocaine. Etomidate exposure in infant mice does 
not induce enhanced apoptosis or changes in long-term motor behaviour in an animal 
model.
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91 Introduction
Every year several millions of surgeries and various diagnostic procedures are 
conducted on infants and children worldwide. Unlike in the adult population 
most of these events have to be performed under general anaesthesia.
Anaesthesia, from Greek an-, “without”; aisthēsis, “sensation”; is defined as 
loss of sensation and can be with or without loss of consciousness. When the loss 
of sensation is combined with a loss of consciousness it is described as general 
anaesthesia (GA). Regional anaesthesia on the other hand, can be described as a 
“nerve block”, which anesthetizes a part of the body with no effect on conscious-
ness. General and regional anaesthesia can also be combined. 
GA is divided into three different phases: induction, maintenance and emer-
gence. The induction of anaesthesia is accomplished either by inhaling a volatile 
anaesthetic gas with a face mask or by injecting an anaesthetic drug intravenously.
The intravenous (i.v.) or parenteral route is today often the preferred alterna-
tive, especially in the adult population, since this method is perceived as being 
both faster and smoother. It is also by many anaesthetists considered as a safer 
option. Furthermore, the intravenous route is favoured when a quick response is 
requested, e.g. rapid sequence induction (RSI). The maintenance of anaesthesia 
can be achieved either by continuing the i.v. drug used for induction as an infu-
sion (total intravenous anaesthesia-TIVA) or by inhaling an anaesthetic gas.
The most frequently used i.v. induction agent today is propofol, a short-act-
ing hypnotic and amnestic agent.  The former most common i.v. induction agent 
thiopental is currently less used, one major reason being longer residual sedation 
compared to propofol.
One specific adverse effect of propofol is injection pain, a very undesirable 
disadvantage especially in infants and children. Studies performed both in chil-
dren and adults have reported an incidence of injection pain of 30-90 %.1-3  Vari-
ous strategies, the most common being the addition of the local anaesthetic li-
docaine, have been used to reduce the incidence but injection pain still remains 
20-40%.1-3 
A current concern of huge importance is the long-term safety following an-
aesthesia exposure in neonates and infants.  Numerous studies in rodents and 
non-human primates have shown that almost all anaesthetic agents common-
ly used today are believed to be neurotoxic and cause long-lasting effects on the 
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brain. Because of the large number of infants and children that receive anaesthe-
sia every year the clinical implications of this potential neurotoxicity related to 
anaesthesia at an early age may be very substantial. Until recently the published 
human paediatric studies have been retrospective and the results inconclusive. 
The interim neurodevelopmental results from a human randomized controlled 
trial (RCT) of regional vs general anaesthesia, the GAS study, show that any en-
hanced apoptosis induced by anaesthetic agents does not appear to be clinically 
relevant.4  This and other ongoing prospective studies will hopefully contribute 
to answering the question whether anaesthesia to infants and children is harm-
ful or not.
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2 Background
Historical background of general anaesthesia 
The birth of general anaesthesia is usually attributed to the first successful use of 
ether which was exhibited 16 October 1846. A public demonstration of a surgery 
carried out under ether anaesthesia was then performed at Massachusetts Gen-
eral Hospital (MGH) in Boston. The anaesthetic was delivered by a Boston den-
tist, William T.G. Morton, who during a chemistry lecture at Harvard Medical 
School some years earlier had learned that the easily acquired solvent sulfuric 
ether could turn a person unconscious. After experimenting with several differ-
ent animals, and also testing on himself and friends, Morton started using ether 
as a pain relief for his dental patients.  Convinced of the drug’s safety and qual-
ity, Morton proceeded to demonstrate the favourable features of ether for an au-
dience consisting of surgeons and medical students at MGH’s operating theatre. 
The patient was a young man, Edward Gilbert Abbot, who had a tumour on his 
jaw removed. The surgeon was John Warren, who after the successful operation, 
during which the patient seemed to experience no pain at all, uttered the famous 
words “Gentlemen – this is no humbug”. The operating theatre ”The Ether Dome” 
is still preserved, open to the public and on October 16 every year ”Ether day” is 
celebrated at MGH. A monument honouring the first use of ether as an anaes-
thetic is located in the Boston Public Garden. One of the four inscriptions on the 
monument says: “To commemorate that the inhaling of ether causes insensibility 
to pain. First proved to the world at the Mass. General Hospital in Boston, October 
A.D. MDCCCXLVI”
Induction of anaesthesia
Induction of anaesthesia can be accomplished either by inhalation of a volatile 
anaesthetic with a face mask as first demonstrated by Morton (e.g. ether, halo-
thane or currently sevoflurane) or by intravenous injection of an anaesthetic in-
duction agent (see below). Inhalational induction of anaesthesia in children is 
even today still quite commonly used in large parts of the world since establish-
ing intravenous access may be difficult in paediatric patients. However, following 
the introduction of EMLA® (Eutectic Mixture of Local Anaesthetics), a Swedish 
innovation that provide cutaneous anaesthesia, intravenous induction of anaes-
thesia has become popular also in children, not only in Scandinavia but from a 
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global perspective as well.
The current thesis has a focus on intravenous induction of anaesthesia in chil-
dren and will not further discuss inhalational induction.
Intravenous induction of anaesthesia
Prior to the early 1930’s general anaesthesia was solely provided by either ether 
or chloroform. However, at this time the drug class barbiturates was discovered 
and was initially used to treat anxiety and sleeping disorders as oral preparations. 
This was soon followed by the development of intravenous preparations that were 
found capable of inducing anaesthesia. The first successful induction of anaesthe-
sia by intravenous injection of a barbiturate is often attributed to John S. Lundy 
at the Mayo Clinic (Rochester, USA).  Lundy introduced the i.v. barbiturates so-
dium amobarbital (1929) and sodium pentobarbital (1930) for clinical use in an-
aesthesia. Furthermore, the concept of “balanced anaesthesia” was introduced by 
Lundy already in 1926.5, 6  
The short acting i.v. barbiturate sodium thiopental (Pentothal®) was clinically 
introduced in 1934 by Ralph M. Waters at the University of Wisconsin Medical 
School (Madison, USA). Waters was the world’s very first professor in anaesthesi-
ology and also became the first honorary member of the Swedish Society of An-
aesthesiologists. In appreciation for his contributions to the development of an-
aesthesiology in Sweden, Waters received the Order of Wasa from King Gustav V 
of Sweden in 1947. 
Sodium thiopental totally dominated the market for the next 50 years. De-
spite the dominance of thiopental a number of different intravenous induction 
agents was developed but fell into disuse for various reasons, e.g. Nembutal®, Bri-
etal®, Epontol® and Althesin®.
With the introduction of new intravenous induction agents (e.g. propofol) 
that possessed better characteristics than thiopental, this classic intravenous in-
duction agent is much less used today. An example of this is that only a few drug 
companies still produce this drug and at times it is difficult to get thiopental de-
livered in a reliable fashion. Furthermore, thiopental has come to get a question-
able reputation since it in the USA has been used as a component of the drug mix 
used for intravenous executions. However, thiopental may still represent a useful 
alternative for induction of anaesthesia in small babies since the more modern 
alternative propofol may cause pronounced and quite prolonged hypotension in 
this patient category. 7-10 
Here follows information about three different i.v. anaesthesia agents com-
monly used in clinical practice today and that are part of the different studies in-
cluded in this thesis.
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Propofol
Propofol (2, 6 – Di-isopropylphenol) is now the dominating i.v. agent throughout 
the world due to its favourable properties being a smooth induction and fast re-
covery. The anaesthetic effect of propofol is believed to be mediated mainly via ac-
tions at the γ-aminobutyric acid type A (GABAA) receptor.11, 12 
Propofol is not only used for induction but also for maintenance of anaesthe-
sia either alone or combined with other drugs. It is especially suitable for day-sur-
gery because of the quick recovery- this in contrast to the former most used in-
duction agent thiopental. The use of propofol has expanded from being merely an 
anaesthetic agent used for induction and maintenance to also include sedation in 
intensive care units and out-patients procedures. 
Propofol is not (especially in children) recommended for long-term sedation 
because of the risk for propofol infusion syndrome (PRIS) that is potentially fatal. 
PRIS was initially described in the paediatric population 13, 14 but PRIS has also 
been reported to occur when critically ill adults have been sedated with propo-
fol.15, 16
The syndrome was defined by Bray in 1998 as: “(1) the sudden, or relative-
ly sudden, onset of a marked bradycardia which was resistant to treatment and 
which progressed to asystole; (2) the presence of lipaemic plasma; (3) a clinically 
enlarged liver or one which was found to be infiltrated with fat at autopsy; (4) the 
presence of a metabolic acidosis to the extent of at least one arterial blood sample 
with a base deficit greater than 10; (5) the presence of muscle involvement with 
evidence of rhabdomyolysis or myoglobinuria”. According to Bray bradycardia (1) 
and at least one of (2), (3), (4), or (5) have to be present in order to define the condi-
tion as PRIS. Bray’s recommendation was to limit the duration to < 48 hours and 
use dose of less that 4mg/kg/h.
Even with shorter duration and when propofol have been used exclusive-
ly during anaesthesia PRIS is suspected to have occurred, both in children and 
adults.17-20
A normal induction dose of propofol produces a 20–40 % reduction in blood 
pressure during induction which is caused by arterial vasodilation due to reduced 
vascular sympathetic tone, but also by a direct effect on myocardial contractil-
ity.21-24
Another known adverse effect is a dose-dependent depression on ventilation 
and apnoea is often seen during induction.1, 21, 25
Propofol is a phenol and like other phenols it irritates skin, mucous mem-
branes as well as the venous intima. Initially propofol was solved in Cremophor 
EL – a castor oil - but due to a high incidence of anaphylaxis and very high fre-
quency of pain on injection the product (by name ICI 35868) was withdrawn 
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from the market.  The emulsion eventually chosen as a solvent was the one with 
the same components as the parenteral fat formulae, Intralipid® that contains soy-
bean oil (long chain triglyceride-LCT), egg yolk lecithin and glycerol. Even with 
this lipid-formula the incidence of pain still remained unacceptable high- around 
60-70 %.2, 3, 26
The mechanism of the propofol-induced injection pain is not fully under-
stood but is believed to be caused either by a direct stimulation of pain receptors 
in the venous wall or by an indirect stimulation which leads to release of differ-
ent mediators (kinin cascade) that stimulates nerve endings and causes late onset 
of pain.27
Since the introduction of propofol countless attempts have been made in ef-
fort to minimize both the incidence and the intensity of propofol-induced injec-
tion pain. Various drugs, such as antiemetics, non-steroidal anti-inflammatory 
drugs, β blockers, 5-HT3 receptor antagonists, lidocaine and opioids have been 
used more or less successfully.2, 3, 28  Propofol has been given slow, fast, cooled or 
warmed without any proven pain-reducing effect. 
The introduction of a novel lipid-formula (Propofol-®Lipuro), which contains 
medium chain triglycerides (MCT) together with soya bean oil, have in some 
studies shown a reduction in pain incidence29-33 while other studies have not been 
able to confirm these results.34, 35
Of all the numerous interventions and agents that have been tested in the at-
tempt to reduce propofol-induced injection pain, the local anaesthetic lidocaine 
(Xylocaine®) is the most commonly used option in clinical practice. Its effect is 
believed to be caused by a direct action but may also be due to a decreased pH of 
the lipid emulsion, which in turn decrease the free propofol concentration in the 
aqueous phase.36
Today the recommendation for reducing injection pain is to choose an as big 
vein as possible, e.g. the antecubital vein that has a larger diameter than the veins 
on the dorsum of the hand. If the hand is chosen pre-treatment with lidocaine in 
conjunction with venous occlusion is advocated.3  Lidocaine can also be given as 
a pre-treatment without venous occlusion before the induction with propofol or 
mixed (admixture) with the propofol in the same syringe directly prior to injec-
tion. These interventions have however been observed to be somewhat less effi-
cacious compared to pre-treatment with lidocaine combined with venous occlu-
sion.2, 3
Another current advice is, in addition to the pre-treatment or admixture with 
lidocaine, to also include an opioid before the induction of the anaesthesia (if not 
contraindicated).3
A recently published review focuses on the effect of lidocaine in reducing 
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high intensity pain caused by propofol, including 87 studies and a total of 10.460 
adult subjects. Six sub-groups from the different studies were identified: (1) low 
dose lidocaine admixture - ≤ 20mg or  ≤ 0,2 mg/kg, (2) high dose lidocaine ad-
mixture - >20 mg or > 0,2 mg/kg, (3) low dose lidocaine pre-treatment alone - ≤ 
20mg or  ≤ 0,2 mg/kg, (4) high dose lidocaine pre-treatment alone - >20 mg or > 
0,2 mg/kg, (5) low dose lidocaine with venous occlusion-≤ 20mg or  ≤ 0,2 mg/kg, 
(6) high dose lidocaine with venous occlusion- >20 mg or > 0,2 mg/kg. The main 
results from this meta-analysis are that lidocaine is capable of significantly re-
ducing high intensity pain and also to reduce the overall incidence of pain.  The 
least efficient method appears to be pre-treatment with low dose lidocaine alone. 
A subgroup analysis of the dose of lidocaine suggests that a higher dose is more 
effective for reducing and preventing propofol-induced pain than a lower dose in 
both the admixture and the pre-treatment groups.28  The authors conclude that 
all methods are effective and the preferred option should therefore be used ac-
cording to the circumstances.    
It is well known that the incidence of propofol-induced pain is higher in chil-
dren.1, 26  One obvious reason for this is that veins have smaller dimensions in pae-
diatric subjects. The recommended antecubital vein is not always easy to access in 
children and is less favoured since extravasation more easily can be overlooked. 
Another drawback is that the antecubital vein easily occludes when the elbow is 
flexed. To apply a venous occlusion is seldom possible in the paediatric popula-
tion since it can be uncomfortable for the child and also more time-consuming. 
Instead the most common procedure and the only option proven to be effective is 
to mix the propofol with the local anaesthetic lidocaine prior to injection. Doses 
of lidocaine required to have effect is somewhat higher compared to adult data: 
0.2 mg/kg instead of 0.1 mg/kg.26 A more dilute propofol preparation, consisting 
of 0.5% propofol instead of 1 % in a lipid solution, has been shown to reduce the 
pain-incidence in children.37 However, it still remains an unacceptable high 23 %.
Etomidate 
Etomidate (D-Ethyl-1-(α-methylbenzyl)-imidazole-5-carboxylate) is an imidaz-
ole derivate with the same favourable properties as propofol: fast onset and quick 
recovery. Etomidate’s anaesthetic effects are considered to be mediated mainly via 
actions at GABAA receptors.11, 38, 39
Etomidate does not affect myocardial function or sympathetic tone which 
makes it a haemodynamically very stable drug. After a normal induction dose 
only a minimal change in heart-rate and blood-pressure is usually seen.21, 24, 40 
Furthermore, unlike propofol and barbiturates very minimal respiratory depres-
sion is noted.21
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Etomidate is hydrophobic at physiologic pH so to increase solubility it is ei-
ther solved in propylene glycol (Amidate®, Hypnomidate®) or in a lipid emulsion 
(Etomidate-®Lipuro). The solvent based on propylene glycol is known to induce 
injection pain in 60-80 % if no adjuvant is given and there is also a high associ-
ated risk for thrombophlebitis and thrombosis.41, 42 However, when solved in soy-
bean oil and MCT the pain incidence is virtually zero and no venous irritation is 
noted in adults.43, 44
One side effect of etomidate is the occurrence of myoclonic movements (MM) 
that occur in 50-80 % of patients during induction.45 The incidence and intensity 
in adults is related to the dose and can be attenuated by premedication with ben-
zodiazepines, dexmedetomidine, opioids, ketamine or a split-dose induction.45-51
The MM are not connected to seizure-like EEG (electroencephalogram) ac-
tivity, instead it is postulated that the myoclonus is a phenomenon of subcortical 
disinhibition, much like the phenomenon of restless legs during normal human 
sleep.45  It is worth noting that myoclonic activity is also seen after propofol in-
duction with an incidence of approximately 6 -15 %.52-54
Another side effect that has raised concern about the safety of etomidate is the 
inhibition of corticosteroid synthesis. When etomidate is used as an infusion to 
maintain anaesthesia, the concentrations of cortisol, cortisone, and aldosterone 
decrease in plasma and furthermore the concentrations of 11-deoxycorticoste-
rone, 11-deoxycortisol, progesterone, and 17-hydroxyprogesterone increase. It is 
believed that etomidate inhibits adrenal steroid synthesis principally by blocking 
the activity of 11β-hydroxylase.55, 56 This mitochondrial cytochrome enzyme con-
verts 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. 
Contrary, the effect of a single induction dose of etomidate does not appear to 
cause clinically relevant interference with corticosteroid synthesis.57-59
Figure 1 
Structure of etomidate
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Ketamine
Ketamine (2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride), 
represents another well-known anaesthetic agent that is assessed in study IV. Ef-
fects of ketamine are believed to be mediated mainly by inhibition of the N-meth-
yl-d-aspartate (NMDA) receptor.11, 39
There are two optical isomers of ketamine: S (+) ketamine and R (-) ketamine. 
S (+) Ketamine (Ketanest®) is about twice as potent compared to racemic ket-
amine and possibly cause less adverse effects.60-62
Ketamine can be used for both induction and maintenance of anaesthesia 
and is especially popular in prehospital and trauma settings as it maintains cir-
culation and respiration.63, 64  Since ketamine has analgesic properties at sub-an-
aesthetic blood concentrations it also makes it suitable for postoperative analge-
sia and sedation.65
The intravenous administration of ketamine is not known to be associated 
with any noticeable injection pain.66
Emergence delirium and psychotomimetic side effects are not uncommon 
when using ketamine and benzodiazepines has traditionally been recommend-
ed in order to reduce these problems.67 More recent paediatric studies contra-
dict this previous custom and instead suggest that benzodiazepines do not reduce 
emergence reactions and postoperative reactions.68, 69 
In some countries ketamine is used as a recreational drug known as “Special 
K”, “Kit-Kat” and “Cat Valium”.70  Apart from the obvious concerns with drug 
addiction and its related problems (e.g. acute toxicity and chronic psychological 
effects) a prolonged use of ketamine has been noted to cause urinary bladder in-
flammation with ulcerative cystitis. The reason why ketamine cause cystitis is un-
clear.71
Recent studies have shown that ketamine and other NMDA receptor modu-
lators possibly can possess effects in treating therapy resistance depression (major 
depressive disorder, MDD).72, 73  However, a review report including 25 studies 
found limited evidence for ketamine’s efficacy over placebo and the authors con-
cluded that further RCTs with adequate blinding and longer follow up are needed 
in order to evaluate the effects of ketamine on MDD.74
Regarding potential neurotoxicity ketamine is one of the most thoroughly 
studied anaesthetic agents.
Here follows a brief description of the mechanisms of general anaesthesia.
Molecular mechanisms of anaesthesia
Anaesthetics agents are believed to produce their main target-effect via interac-
tion with GABAA and/or NMDA receptors.11, 39, 75, 76
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Gamma-Amino Butyric acid (GABA) is an amino acid that acts as an inhibi-
tory neurotransmitter in the central nervous system (CNS) and GABAA recep-
tors are the major inhibitory neurotransmitter-gated ion channels in the human 
brain. The GABAA receptor, which belongs to a superfamily of ligand-gated ion 
channels, is a pentameric structure around a central pore, located partly extracel-
lularly, partly intracellularly. So far 19 different subunits have been identified and 
in different combinations they include about 50 different GABAA sub-receptors. 
When GABA binds to the GABAA receptor it produces an influx of chloride into 
the cell that makes it slightly more negative and causes an inhibitory postsynap-
tic effect.   
Drugs that mainly act on the GABAA receptor are (apart from endogen 
GABA) the positive allosteric modulators (agonists) benzodiazepines, barbitu-
rates, propofol, etomidate, volatile agents and ethanol. By increasing the activity 
of inhibitory GABAA receptors the neuronal excitability is reduced and the effects 
are amnesic and hypnotic. A negative allosteric modulator is flumazenil (Fluma-
zenil®, Lanexate®), a drug that can be used in treating benzodiazepine overdose.
While GABA is an inhibitory transmitter in the mature brain, its actions are 
primarily excitatory in the developing brain.77 The intracellular chloride levels 
are higher in the immature neurons than in adult neurons but the mechanism 
and implications for this is unknown. The fact that the incidence of seizures is 
highest early in life could possibly be related to that GABA excites the immature 
neurons.78
The major excitatory neurotransmitter-gated ion channels in the human 
brain are the glutamate receptors. To this family the NMDA-receptor belong 
which unlike the pentameric GABAA receptor is composed only by four sub-
units. The NMDA receptors are activated by endogenous glutamate and aspar-
tate. When glutamate is released from the presynaptic neuron by an action po-
tential this leads to a flow of calcium and sodium into the cell and potassium out 
of the cell which produces an excitatory postsynaptic potential. 
Agents that work mainly through NMDA receptor antagonism are ketamine, 
nitrous oxide, ethanol, xenon, diethyl ether and cyclopropane.39, 75
Both molecular (in-vitro) and animal studies involving transgenic mice 
have shown that different anaesthetics have different degrees of target selectiv-
ity. Anaesthetic drugs can according to some authors be divided into three differ-
ent groups. Group 1 drugs (propofol, etomidate and barbiturates) act primarily 
through specific GABAA receptors associated with different subunit types. Group 
2 drugs (ketamine, nitrous oxide, xenon and cyclopropane) seem to act on a small 
number of targets, including glutamate receptors and two-pore potassium chan-
nels. Group 2 have in clinical concentrations minimal effect on GABAA recep-
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tors.  Group 3 (volatile anaesthetics) are the least selective group which affects 
many possible molecular targets such as GABAA and two-pore receptors. Stud-
ies show that hypnosis and amnesia seem to be linked to enhancement of GABAA 
receptors for both group 1 and 3 anaesthetics.  Analgesia correlates strongly with 
NMDA receptor inhibition, a quality possessed especially by anaesthetics in 
group 2.39  Recent studies have indicated that other receptors for example HCN1 
(hyperpolarization activated cyclic nucleotide gated potassium channel 1) can be 
targets for both volatile anaesthetics and ketamine.79, 80  Due to these new stud-
ies the targets and effects of anaesthesia are somewhat better understood and un-
doubtedly more specific and improved agents with less unwanted side-effects will 
hopefully be developed.39
As alluded in the Introduction, virtually every commonly used anaesthetic, 
whether volatile or intravenous, have been shown to produce neurotoxicity in 
preclinical studies on rodents and non-human primates.
Neurotoxicity
Developmental neurotoxicity (DNT) is defined as: “any adverse effect on the 
chemistry, structure and function of the nervous system during development or 
at maturity, induced by chemical or physical influences”.81 The definition of DNT 
also includes changes in behaviour, brain morphology and neurochemistry after 
gestational and/or lactational exposure. It is today widely accepted that the devel-
oping brain is more sensitive to the effects of different chemicals than the adult 
brain.82, 83 The incidence of human neurodevelopmental diseases such as atten-
tion deficit, hyperactivity disorders, autism and others is increasing.84  The rea-
son for this is not fully understood, but is believed to be caused by different ge-
netic and social components in addition to chemicals in the environment.85 Since 
many years it has been known that several compounds that can be found in our 
environment, e.g. lead, methylmercury and polychlorinated biphenyls are harm-
ful to the child’s development.86
Worries about the potentially negative effects from GA emerged in the 1950’s 
when personality changes were observed following anaesthesia.87  Some decades 
later a concern arose regarding the possible health hazard for pregnant health 
care workers and anaesthetic waste gases (halothane). In a study by Quimby and 
co-workers where rats exposed to subclinical doses of halothane (10 ppm, which 
was then an accepted threshold value in an operating room) 8 hours/day for 5 
consecutive days, were later found to display impaired behaviour and histopatho-
logical changes in the brain.88
A ground-breaking study in 1999 from Ikonomidou and colleagues, where 
the NMDA-blocking agent dizocilpine (MK801) was found to cause widespread 
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neurodegeneration in neonatal rats, raised the question of potential deleterious 
effects of other NMDA receptor blocking anaesthetic drugs.89 A few years later 
a study by Jevtovic-Todorovic and co-workers found that a combination of the 
GABA-agonist midazolam, the combined GABA-agonist and NMDA-antagonist 
isoflurane and the NMDA-antagonist nitrous oxide given to neonatal rodents not 
only caused substantial loss of brain-cells by enhanced apoptosis but also caused 
persistent memory and learning impairments.90
 After these initial studies a large number of related experiments have been 
performed. Several research groups have in animal studies reported various ex-
pressions of DNT after anaesthesia exposure– such as acute cell-death, changes in 
dendritic architecture, reduced synaptic density, decreased levels of neurotrophic 
factors, mitochondrial degeneration, destabilization of the cytoskeleton, cell cycle 
abnormalities and altered behaviour.91-112 
To understand the mechanisms which could potentially lead to these aber-
rations some basic knowledge about normal development of the central nervous 
system (CNS) is advantageous.
Brain development
The sequence of brain development does not vary significantly between different 
mammalian species, but the time-span is different depending on animal specie. 
A way to compare diverse neural events between species is to access www.transla-
tingtime.org.  18 various mammalian species, including humans, are part of this 
model which makes it easier  for researchers to compare data obtained in studies 
performed on different laboratory animals.113
In the first embryonic part of CNS development the brain obtains its form by 
proliferation, migration and differentiation. The embryonic brain development is 
followed by the foetal developmental period when functional circuits in the brain 
are formed and matured. A particularly vulnerable period during this period is 
called the “brain growth spurt” (BGS). During the BGS the brain rapidly expands 
in weight and size mainly caused by an increase of glia cells. Other processes oc-
curring during BGS are growing and maturing of neurites, establishment of neu-
ral connections, synaptogenesis and myelination.83  
Early studies in the 1970’s by Dobbing and Sand found differences in brain 
development between species by simply weighing the brains post-mortem. The 
definition of BGS was then defined by the total brain weight gain as a percent-
age of its adult weight.82, 114  Today it is commonly accepted that the BGS period 
starts to appear in humans from the last trimester to the first 2-3 years after birth. 
In rodents BGS is solely neonatal with a peak around postnatal day (PND) 7-10 
and continues during the first month in life.83  Synaptic pruning, the process by 
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which unwanted or unused synapses are eliminated, continues in humans up un-
til adolescence. By then nearly 50 % of the synapses that were present at 2 years 
of age are abolished.
Before the introduction of magnetic resonance imaging (MRI) it was general-
ly believed that the brain was fully developed by the age of six but today we know 
that the function and morphology of the brain is a continuous lifelong process. 
This development depends on the genetic set-up, the internal and external envi-
ronment, and of course on experience. At adulthood the mature brain consists of 
>100.000 billion neurons. Each neuron can be connected (synapse) with 1000’s 
of other neurons which results in an endless number of neuronal connections or 
neuronal circuits. All this taken together makes the brain by far the most refined 
and complex organ in the human body.83 
Apoptosis
A requirement for normal development is apoptosis which is also known as pro-
grammed cell death. This is a naturally occurring cellular “suicide” where re-
dundant or possibly harmful cells are eliminated. Apoptosis, which can affect 
individual or smaller groups of cells, is an energy-consuming process with no 
inflammatory response. The process involves the activation of a group of cys-
teine proteases: “caspases” (proteases= enzymes that degrade proteins). It is an 
extremely complex process and is believed to occur mostly through two main 
pathways, the extrinsic and the intrinsic pathway.  Each pathway requires certain 
triggering signals to start a cascade of molecular events. The extrinsic pathway 
involves binding of ligands to death receptors [members of the tumour necro-
sis factor (TNF) receptor gene super family] in the transmembrane, which leads 
to activation of Caspase-8 which in turn activates the final step: the executioner 
or activated caspase-3 (AC-3). The intrinsic pathway or the mitochondrial path-
way is non-receptor mediated and is initiated by stimulus such as radiation, hy-
perthermia, infections, toxins as anaesthetics, etc.  All these stimuli initiates an 
increase in the mitochondrial membrane permeability which leads to a release of 
pro-apoptotic proteins (cytochrome c most essential) into the cytosol. This results 
in an activation of caspase-9 which subsequently activates caspase -3. Both the ex-
trinsic and intrinsic pathways end at the point where capase-3 is activated. Here 
the “execution pathway” starts which results in fragmentation of DNA, degrada-
tion of nuclear/cytoskeletal proteins and formation of apoptotic bodies which are 
subsequently engulfed by macrophages. AC-3 is considered to be the most im-
portant of the executioner caspases and has frequently been used as a marker to 
quantify neuroapotosis caused by anaesthesia.115, 116 
Necrosis is the other major death process. In contrast to apoptosis, necrosis is 
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a passive, non-energy consuming process that usually affects larger fields of cells 
and also activates inflammation.115 
Methods to measure apoptosis  
and neurodegeneration
There are various methods to measure apoptosis and neurodegeneration, all with 
their pros and cons. One traditional method is to evaluate cytomorphological al-
terations detected by staining and then assessed by microscopy. When the effects 
of anaesthetics are investigated the Fluoro-Jade method often has traditionally 
been used. These techniques have, as several others, difficulties to differentiate 
apoptosis from necrosis.117  
Another method to estimate apoptosis is to measure DNA fragmentation by 
the TUNEL (terminal dUTP nick end-labeling) method.  Array kits are commer-
cially available but the method is regarded as expensive, time-consuming and 
often show false positive results.117  The activation of different caspases can be 
detected in a variety of ways (western blot, immunoprecipitation and immuno-
histochemistry). However, one disadvantage is that caspase-activation may occur 
but does not necessarily result in enhanced apoptosis.115,117 
Most animal studies concerning anaesthesia and neurotoxicology focus on 
different ways to measure apoptosis and various other structural signs of neuro-
degeneration. Some studies in addition to this also measure neurodevelopmental 
outcome after anaesthetic exposure to support the potential importance of en-
hanced apoptosis. (See below). 
Behavioural animal tests
In addition to different in-vitro measurements the potentially deleterious effects 
of anaesthesia have also been assessed by various animal behavioural tests. One 
method to evaluate normal behaviour in rodents is to measure spontaneous mo-
tor activity in a novel home environment. The decrease in activity over time is a 
normal profile of spontaneous behaviour and referred as habituation. This test 
can be said to represent a crude measurement of cognitive function.118  Other be-
havioural tests commonly used in rodents are e.g. Radial Arm Maze, Morris Wa-
ter Maze (two tests that assess learning capability, specifically working memory 
and spatial memory) or Elevated Plus Maze test (an exploration- and interaction-
based anxiety test).119 
In non-human primates (rhesus monkeys) other more refined test as Operant 
Test Battery (OTB) have been performed to determine the possible negative effect 
of anaesthesia on the developing brain.103, 120 
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Epidemiological studies
The numbers of human studies are rather limited compared to the vast amount 
of animal studies. For obvious reasons it is not possible to examine brain tissue in 
healthy children so all the human studies depend on assessing neurological func-
tions. Some epidemiological studies have demonstrated an association between 
early-life exposure to anaesthetics and altered long-term neurocognitive outcome 
while others have not. Thus, so far the results are inconclusive.
A series of retrospective epidemiological cohort studies have been published 
by the Mayo group. The studies are based on the same birth cohort consisting of 
5.357 children that were born between 1976 and 1982 in Olmsted County, Min-
nesota, USA.   In these studies Wilder et.al used the fact that the children had al-
ready been evaluated in terms of learning difficulties.  
In their first study 593 children that had anaesthesia (predominately halo-
thane and nitrous oxide) exposure before the age of 4 were compared with 4.764 
children with no exposure.121 One exposure did not affect the outcome but chil-
dren who had 2, 3 or more suffered 1.59–2.6 times more often from learning dis-
abilities compared to the un-exposed group.
Using the same cohort Wilder et al. compared 359 children who had anaes-
thesia and surgery before the age of 2 with 5.007 children who did not.122 Again- 
one exposure did not increase the risk for learning disabilities but children who 
had more than two exposures were 1.95 times more likely to be diagnosed with 
ADHD (attention-deficit hyperactivity disorder) compared with the non-exposed 
group.
The Mayo group studies do have some weaknesses.  One concern is that al-
most one third of the original cohort moved from the county during the study 
period and data from those children were lost to follow up. Furthermore, a selec-
tion bias probably occurred since families with sick children were possibly less 
likely to move from the area and instead preferred to stay close to the hospital. 
Additionally, children suffering from different chronic diseases are more prone to 
require frequent anaesthetics and may also have various degrees of learning dis-
abilities. 
To correct for the latter sicker children with American Society of Anesthesiol-
ogists (ASA) physical status 3 and 4 were excluded in a subsequent study but even 
then the anaesthesia group scored worse.123 In this study very few children <1 
year were included. Furthermore, all types of surgeries were included and known 
confounding factors were not taken into consideration. 
In two retrospective cohort studies DiMaggio et al. analysed children born 
between 1999 and 2002 that were enrolled in the New York State Medicaid pro-
gram. In their first study 383 children undergoing surgical hernia repair before 
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the age of 3 were compared with 5.050 with no surgery.124 Even after adjusting for 
known confounding factors developmental or behavioural disorders were twice 
as common in the hernia repair group as in the control group. Type of anaes-
thesia, frequency or the duration was not accounted for. The second retrospec-
tive study performed by DiMaggio involved siblings born between 1999 and 2005 
(twins of unknown zygocity) where 304 children of a cohort consisting of 10.450 
had anaesthesia younger than 3 years and 10.146 had not. A 60 % greater risk to 
be diagnosed with developmental and/or behavioural disorders was found in the 
exposed group.125
The studies by DiMaggio et al. used data obtained from a health insurance 
organization program that relates to the poorest population in New York State 
where the frequency of important diagnoses e.g. mental illness could be higher. 
ICD-9 codes (International Classifications of Diseases- 9th revision) were used to 
define both enrolment and outcome which also could influence the results.
In the Netherlands Bartels et al. used the national twin registry to study 1.143 
monozygotic twin pairs (born 1986-1995) where both, one or none of the twins 
had surgery before 3 year of age. At the age of 12 when the children were tested by 
teachers’ ratings and standardized tests the exposed group was found to perform 
worse. However, 15 % (71 twin pair) were discordant for anaesthesia, i.e. one twin 
had undergone anaesthesia, and the co-twin had not. An interesting finding was 
that the unexposed twin in a discordant pair did not differ from its exposed sib-
ling which could indicate that factors other than anaesthesia are responsible for 
the developmental impairment.126   
In Denmark Hansen et al. performed a follow-up study of the Danish birth 
cohort from 1986 to 1990 in order to investigate the association between an-
aesthesia and surgery for inguinal hernia repair in infancy and later academic 
achievements. During these years 2.689 children in Denmark had inguinal repair 
surgery before the age of 1. The age-matched control group was a 5 % population 
sample (14.575 children) randomly selected within the cohort. The performance 
of the exposed children was inferior when tested in 9th grade but after adjusting 
for known confounders no difference was found between the groups.127 
A similar study of the same cohort (1986–1990) included 779 neonates who 
were less than 3 months when undergoing pyloric stenosis repair. They had sim-
ilar academic achievements when tested in adolescence compared to the 14.665 
controls.128 However, the non-attainment rate when tested in 9th grade was some-
what higher for the exposed group in both the hernia and pyloric study.  
The Hansen group has also recently shown that when comparing 228 chil-
dren from the same cohort (1986-1990) who had undergone neurosurgery in in-
fancy, the exposed group had a higher mortality rate and also performed signifi-
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cantly less well when tested at adolescence. The key implication of this study is 
not to merge all different surgical procedures together when studying the effect of 
anaesthesia on the developing brain.129 
In Western Australia Ing et al. performed an analysis on an established preg-
nancy cohort (the Raine study – initially created to evaluate long-term effects of 
pre-natal ultrasound).  Of 2.608 children (born from 1989 to 1992) assessed, 321 
were exposed to anaesthesia before the age of 3. When tested at 10 years of age the 
anaesthesia group had displayed deficits in abstract reasoning and language com-
pared to the control group. In contrast motor-function and behaviour were not 
affected.130 All types of surgeries were included, also myringotomies, a circum-
stance that is known to be associated with language and learning problems and 
appears as a plausible explanation for these findings.131    
Another study from Ing et al. used the same cohort. In this study 781 children 
were included and of these 112 had been exposed to anaesthesia before 3 years of 
age. Three outcomes were investigated: academic achievement, ICD-9 codes, and 
direct neuropsychological testing. Deficits were found in the exposed group when 
direct neuropsychological testing and ICD-9 codes were compared but no differ-
ence in the academic achievement was found.132 Both studies have interrelated 
outcomes and use multiple tests that could influence the results.133   
Since complete cognitive testing is extremely time-consuming and expensive 
this often leads to studies with very small study populations. An example of this 
is a study by Stratmann et al.134 where only 28 children between 6-11 years of 
age, who had various surgeries before age 1 were included. The age and gender 
matched control group also consisted of only 28 children. After extensive testing 
the children in the anaesthesia group were found to have significantly lower rec-
ollections scores and performed worse regarding recollection of associative infor-
mation while IQ and child behaviour checklist scores were unaffected.
In summary it can be concluded that epidemiological retrospective studies 
are limited by numerous confounders. The results are therefore unfortunately in-
conclusive and in order to try to answer the question if early exposure to anaes-
thesia may be neurotoxic or not, additional prospective randomized studies are 
necessary. 
Ongoing prospective randomized studies
The GAS study (general anaesthesia vs regional anaesthesia) is a multicentre tri-
al with 28 participating hospitals in Australia, Italy, the USA, the UK, Canada, 
the Netherlands and New Zealand where infants < 60 gestational age, born > 
26 weeks of gestation scheduled for inguinal hernia repair were randomly as-
signed to either general anaesthesia (sevoflurane based) or regional anaesthesia 
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(spinal or caudal). Between 2007-2013 a total of 722 infants were enrolled; 363 
in the awake group and 359 in the general anaesthesia group.  The primary out-
come of the trial will be the Wechsler Preschool and Primary Scale of Intelligence 
Third Edition (WPPSI-III) Full Scale Intelligence Quotient score at age 5 years. 
The secondary outcome, with results recently reported, was assessed at 2 year by 
the composite cognitive score of the Bayley Scales of Infant and Toddler Devel-
opment III (Bayley III).  At this interim analysis no evidence was found that 1 h 
of sevoflurane anaesthesia increases the risk of adverse neurodevelopmental out-
come at 2 years of age compared with awake-regional anaesthesia.4 These results 
are reassuring but the final results of the GAS study are not expected until 2017. 
A further ongoing study is the Pediatric Anesthesia and Neuro-Development 
Assessment (PANDA) study, a multicentre study based at Columbia University 
with 4 participating centres in the USA.  The study start was in May 2009 and the 
estimated completion date December 2016. In this study 500 ASA 1-2 (healthy or 
mild systemic disease) children who undergo inguinal hernia repair under GA 
before the age of 3 are compared with an unexposed sibling. Data are collected 
from a retrospective database.  At the age between 8 and 15 the children will be 
tested extensively with various neurocognitive tests. No results have up till now 
been released.135 
A third ongoing study-the MASK study (Mayo Safety in Kids study) is led by 
researchers at the Mayo Clinic in collaboration with the National Center for Tox-
icological Research (NCTR). This study will compare performance of children 
exposed to anaesthesia on single or multiple occasions before the age of 3 with 
children never exposed. The testing consists of an extensive series of different 
neurocognitive tests, including the Operant Battery Test (OBT), which has been 
used to test cognitive performance in non-human primates.103, 120  The project 
will sample 1.000 children from a cohort of all children born in Olmsted County, 
Minnesota, between the years 1994 and 2007 and the tests will be performed at 
the ages 8-12 or 15-19.136
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3 Aims
Rationale for the thesis
As alluded to in the Introduction and Background sections, injection pain rep-
resents a substantial clinical dilemma in the context of intravenous induction of 
anaesthesia in children when propofol is used. Thus, there is an urgent need to 
find new alternatives how to reduce injection pain to acceptably low levels in this 
setting. Furthermore, new alternatives must be investigated with regards to the 
timely issue of potential neurotoxicity following exposure to anaesthetics in early 
life.  
Specific Aims
• To compare the incidence of injection pain between the former standard LCT 
propofol + lidocaine with the new MCT-LCT propofol formulae  as plain so-
lution (study I)
• To evaluate the incidence of injection pain between LCT propofol + lidocaine 
and etomidate dissolved in a fat emulsion (study II)
• To investigate if a small priming dose of etomidate can reduce the incidence 
of myoclonic movements (study III)
•   To study the effects of neonatal etomidate exposure on cerebral apoptosis and 
adult behavioural effects in an established mouse model (study IV)
28
4  Material and methods
STUDY I-III
Full details can be found in the original articles.
General
Studies I-III were performed in accordance with the declaration of Helsinki and 
approved by the regional ethics review board in Stockholm. Parental and/or in-
dividual consent were obtained in all cases. The investigations were performed at 
Astrid Lindgren Children’s Hospital.
Demographic data
In study I the computer generated randomization resulted in a significant differ-
ence regarding gender distribution between the two study groups. (22 girls in the 
propofol+lidocaine group compared to only 11 girls in the propofol-lipuro group)
Demographic data in the study groups were similar in both study II and III.
Patient population
Study I
83 paediatric patients ASA 1-2 (healthy or mild systemic disease), age range 2-18 
years and scheduled for elective day surgery were enrolled. The children were 
randomized to receive either propofol (Diprivan®) with added lidocaine (previous 
standard) or a new propofol formulation (Propofol-®Lipuro).
Study II 
A total of 110 children ASA 1-2 (age range 2-16 years) scheduled for elective day 
surgery were planned to be included in the study. The patients were randomized 
to receive propofol with added lidocaine or the new lipid formulation of etomi-
date (Etomidate-®Lipuro). The Ethics Committee requested an interim analysis 
which was performed after 80 patients. Due to a clearly significant result in favour 
of etomidate the study was then stopped at the interim analysis point.  
Study III   
80 children ASA 1-2 (age range 1-15 years) scheduled for elective day surgery were 
randomized to receive either a small priming dose of etomidate or a lipid emul-
sion placebo. After the priming dose a standardized induction dose of etomidate 
was administered. 
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Anaesthetic protocol 
Premedication
Following the application of an EMLA® patch (eutectic lidocaine/prilocaine 5 
% patch) all patients had an intravenous cannula inserted on the dorsum of the 
hand. Before transfer from the day-care unit to the operating room intravenous 
midazolam (0. 05 mg/kg) was given as premedication. In study I the patients also 
received paracetamol (40 mg/kg) rectally (previous standard).
Anaesthetic methods
Study I 
After standard monitoring was applied the anaesthetic induction was either by 
propofol with added lidocaine or plain propofol-lipuro. The coded syringes con-
tained 10 ml propofol 10mg/ml with 1 ml lidocaine 10mg/ml added or propofol-
lipuro 10 mg/ml as plain solution. The speed of the injection was similar for both 
study drugs, approximately 0.4 ml/sec, and the total dose given to the patients 
was 3 mg/kg. 
Study II 
The study drugs in study II were either propofol with added lidocaine or 
Etomidate-®Lipuro. The coded syringes contained either 10 ml propofol 20 mg/
ml with added 1 ml lidocaine 20 mg/ml or Etomidate-®Lipuro 2mg/ml.
After application of non-invasive monitoring anaesthesia was induced by the injec-
tion of 0. 15 ml/kg of the study drug (propofol 3 mg/kg or etomidate 0. 3 mg/kg). 
Study III  
Before the patients received a standard induction dose of etomidate they had been 
randomized to either receive a priming dose of etomidate (0. 03 mg/kg = 0. 015 
ml/kg) or a lipid placebo (0.015ml/kg) from a prefilled coded syringe. Sixty sec-
onds later the anaesthesia was induced with etomidate (0. 3 mg/kg = 0. 15 ml/kg).
Assessment of Injection Pain 
Studies I and II
One specially trained nurse anaesthetist (KvH) assessed injection pain according 
to a four-point scale: 1=no pain (no reaction to injection), 2=slight pain (minor 
verbal/facial response or motor reaction to injection), 3=moderate pain (clear ver-
bal/facial response or motor reaction to injection) and 4=severe pain (the patient 
both complained of pain and withdrew the arm).26 The assessment was made 
from the start of the injection to the point when the patient lost consciousness. In 
study II special care was taken to note the pain assessment immediately after the 
patient lost consciousness, thus, before possible myoclonic activity would poten-
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tially occur. This was done in order to preserve proper blinding. After the assess-
ments were performed, the study was terminated, and the anaesthetic was contin-
ued according to the planned surgical intervention.
Assessment of Myoclonic Movements 
Studies II and III
In study II the myoclonic assessment was done immediately after the pain-scor-
ing and during the following 1-2 minutes. In study III the occurrence and degree 
of myoclonic movements was recorded during a 2 min period after the induc-
tion dose was injected. In both study II and III a 0-3 point scale was used: 0= no 
myoclonic movements, 1=minor myoclonic movements, 2=moderate myoclonic 
movements, 3= major myoclonic activity.41, 45  When the assessment of myoclonic 
activity had been performed, the study was stopped and anaesthesia was thereaf-
ter handled as appropriate for the scheduled surgery.
STUDY IV
A more detailed description of material and methods can be found in the origi-
nal article.
General
Study IV was conducted in accordance with the European Communities Council 
Directive of 24th November 1986 (86/609/EEC) after approval from the local eth-
ics committee (Uppsala University and Agricultural Research Council) and by 
the Swedish Committee for Ethical Experiments on Laboratory Animals.  
Animals
Thirty-seven pregnant Naval Medical Research Institute (NMRI) mice were pur-
chased from Scanbur, Sollentuna, Sweden.  Within 48 hours the litters were ad-
justed to 10-14 pups to contain offspring of both sexes in approximately equal 
numbers. On postnatal day 10 (PND 10) the treatment drugs or control (saline) 
were administered by subcutaneous injection. 
The study population consisted of six different treatment groups and each 
treatment group was derived from 3-6 different litters. 
From the six different study groups six animals were randomly assigned for 
analysis of apoptosis. 
The animals intended for neurochemical measurement of AC-3 were sacri-
ficed by decapitation 24 hours after exposure and the brains were then dissected 
on an ice-cold glass plate. Cortex and hippocampus were collected and instantly 
frozen in liquid nitrogen. The brain regions were separately stored at -80° C until 
the final analyses were carried out. 
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Ten animals from each of the six treatment groups were randomly chosen 
for spontaneous behaviour testing at an age of two months. These animals were 
weaned at the age of 4 weeks and then raised in groups of 6-7 animals in a room 
for male mice only. 
To compare with previous studies only male offspring were used for the neu-
rochemical and behavioural recordings. 
Treatment and drugs
The male pups were on PND 10 injected with 0.3, 3 or 10 mg/kg etomidate, 60 
mg/kg propofol, 50 mg/kg ketamine or placebo (saline) by subcutaneous injec-
tion in the neck in a volume of 5 ml/kg.  The doses of propofol and ketamine were 
chosen in order to allow comparison with earlier studies. The drugs were given 
subcutaneously and not intravenously due to the small size of the animals. The 
pups weigh at PND 10 approximately 4-6 grams.
Apoptosis analysis
Cerebral cortex and hippocampus were homogenized and centrifuged. In order 
to relate the concentration of AC-3 to the total protein concentration in the sam-
ples a Bicinchoninic Acid Protein (BCA) assay was done and the total protein 
content was calculated. Then AC-3 was measured with a sandwich enzyme im-
munoassay (ELISA) kit according to the instructions from the manufacturer.   
Behaviour analysis
The spontaneous behaviour in a novel home environment test was performed at 
the age of 2 months. The animals were tested between 8 a.m. and 12 p.m. under 
the same light and temperature conditions as their housing conditions. A total of 
10 mice were randomly picked from 3-4 different litters in each treatment group. 
Motor activity was measured for a 60-min period, divided into 3 × 20 min peri-
ods (0-20, 20-40 and 40-60 min), in an automated device consisting of 12 cages 
(40 × 25 ×15 cm) placed within two series of low and high infrared beams (Rat-
O-Matic, ADEA Elektronik AB, Uppsala, Sweden).137 
Three behavioural variables were measured:
Locomotion: Counting took place when the mouse moved horizontally 
through the low-level (10 mm above the bedding material) grid of infrared 
beams.
Rearing: Movement in vertical plane was registered when the high-level (80 
mm above the bedding material) grid of infrared beams was interrupted.
Total activity: All types of vibration within the cage, i.e. those caused by the 
animal movements, shaking (tremors) and grooming, were registered by a 
sensor (a needle mounted on a lever with a counter weight), connected to the 
test cage.
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Statistical procedures
Power calculation
Study I
Based on our initial clinical experience and the opportunity to detect a 25% dif-
ference in the primary endpoint between groups with an alpha-value <0.05 and a 
beta-value of 80%, a sample size of 40 patients was generated for each group.
Study II
The primary end point of the study was the presence (score 1–3) or absence (score 
0) of injection pain. In accordance with our previous ﬁndings, the power calcula-
tion was based on a conservative 25% incidence of pain in the propofol– lidocaine 
group and an expected pain incidence of 5% in the etomidate-lipuro group. The 
alpha- and beta-values were set at 0.05 and 90%, respectively. With compensation 
for a limited number of potential drop-out cases the total number of patients was 
estimated at 110 (55 patients in each study group). However, the Ethics Commit-
tee demanded an interim analysis so that patients would not be subjected to un-
necessary injection pain if there was a difference in pain incidence between the 
two study groups. Thus, it was decided to include an interim analysis following 80 
patients and if a statistical difference at P<0.02 was present between the two study 
groups at this interim point the study should be stopped. 
Study III
A power calculation was performed based on data from study II54 and adult data 
reported by Doenicke and colleagues.45  The primary goal of the study was to de-
crease the incidence of MM from 80% to 40% with alpha- and beta -values set at 
0.05 and 90%, respectively. On the basis of these parameters, a total study size of 
80 patients (40 patients per group) was suggested.
Statistical analysis 
Study I-II-III
Non-parametric statistical procedures were used in all the analyses. The 95% 
conﬁdence intervals (95% CIs) for proportions were calculated as given in Ott 
and Mendenhall.138 Classiﬁed data from two independent populations were com-
pared by Fisher’s exact test. Classiﬁed data from several independent populations 
were compared by the x chi2 test for independence. The Wilcoxon matched-pairs 
signed-ranks test was used for comparison of two independent data sets. Several 
independent data sets were evaluated by the Kruskal–Wallis test with Dunn’s post-
test. Correlations were assessed by the Spearman rank correlation test. The tests 
were two-tailed and P-values of < 0.05 are described as statistically signiﬁcant.
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Statistical analysis 
Study IV
Evaluation of the AC-3 analysis of apoptosis was made using one-way ANOVA 
(analysis of variance), pairwise testing with Tukey’s HSD (honestly signiﬁcant 
difference) post hoc test.
The data from the spontaneous behaviour tests in a novel home environment 
were subjected to a split-plot ANOVA design and pairwise testing was performed 
using Tukey’s HSD post hoc test.
34
5 Results
Results from Study I
A significantly higher number of patients in group pD (LCT-propofol+ lido-
caine) were pain free (pain score=0) during the injection compared with group 
pL (MCT-LCT propofol) (61.0% vs 33.3%) (P=0.016). (Figure 2)
MCT-LCT 
Propofol
LCT-Propofol  
+ Lidocaine
Results from Study II
The incidence of injection pain, the primary end point of the study, was signifi-
cantly lower in the Etomidate-®Lipuro  group (5.0%; 95 % CI 0.61–16.9%) com-
pared with the LCT- propofol+lidocaine group (47.5%; 95 % CI 31.5 - 63.9%) 
(P<0.001). (The distribution of pain scores is shown in Figure3)
A higher incidence of myoclonic activity was seen in the Etomidate-®Lipuro 
group (85.0%; 95 % CI 70.2–94.3%) compared with the propofol+lidocaine group 
(15.0%; 95 % C 5.7–29.9%) (P<0.001). 
Figure 2
Children with pain-free  
injection of propofol
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Results from Study III
Neither the total incidence nor the degree of MM was found to differ between 
the two study groups. Incidences of MM (score> 0) were observed in 75.0% and 
72.5% of the patients in the etomidate and placebo groups, respectively. The total 
incidence of MM being 73.8% (95 % CI: 62.7–83.0%). Thus, no effect of the prim-
ing dose was seen.
The incidence of MM (score > 0) differed significantly between the age groups 
(P=0.0014) and was found to be significantly higher in the age group 5–10 yrs. 
(90.2%; 95 % CI: 76.8–97.3%) compared with both younger (<5 yrs., 47.1%; 95 
% CI: 23.0–72.2%; P=0.0008) and older children (>10 yrs., 63.6%; 95% CI: 40.7–
82.8%; P=0.01730). (Figure 4)
The MM scores were highest in patients aged 5-10 years (P=0.0021).
Figure 3
Incidence of injection 
pain, Etomidate-®Lipuro  
vs LCT-propofol  with 
lidocaine
Etomidate- 
Lipuro
LCT-Propofol  
+ Lidocaine
Figure 4
Distribution of myoclonic 
movements in three age 
groups of patients.
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Results from Study IV 
Neonatal exposure to etomidate, propofol or ketamine did not affect the con-
centration of AC-3 in neonatal cortex or hippocampus, compared to the control 
group.
In the control group there was a distinct decrease in activity in all the three 
behavioural variables over the three consecutive 20-min. periods (as expected). 
The three etomidate groups (0.3, 3 or 10 mg/kg) and the propofol group did not 
differ from the control group during any of the three consecutive 20-min periods. 
Mice exposed to ketamine showed a significantly reduced activity for all the three 
behavioural variables, locomotion, rearing and total activity, during the first 20-
min period (0–20) compared to the control animals and all the other treatment 
groups. During the third (40–60) 20-min period, the ketamine exposed animals 
displayed a significantly higher activity for all the three test variables, compared 
to the control group and the other treatment groups. (Figure 5)
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Figure 5
Spontaneous motor 
activity of young 
adult mice exposed 
to either saline 
(control), etomidate 
0.3. 3 or 10 mg/kg, 
propofol 50 mg/kg 
or ketamine 50 mg/
kg on postnatal day 
10. Statistical signifi-
cance is indicated 
by A ( p<0.01) vs 
all other treatment 
groups.
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6 Discussion
Aspects on the use of propofol vs. etomidate in  
paediatric anaesthesia and paediatric intensive care
Due to the many desirable characteristics of propofol compared to previously ex-
isting alternatives this compound has become the “gold standard” for intrave-
nous induction of anaesthesia. However, from a paediatric perspective the routine 
use of propofol is associated with some limitations. Below a comparative discus-
sion regarding the use of propofol and etomidate, essentially from a paediatric 
perspective, is provided. 
General considerations
Prolonged intravenous infusions
Propofol
Propofol Infusion Syndrome (PRIS): The exact mechanism of PRIS is still un-
known but is believed to be associated with failure of mitochondrial respiration 
and defects of fatty acid oxidation.139 A recently published rodent study shows 
that propofol interrupts the electron flow in the respiratory chain mainly at the 
site of coenzyme Q.140  There is no diagnostic test for PRIS which is always a pre-
sumed diagnosis and when other causes to the symptoms are ruled out. The treat-
ment is rapid recognition and removal of the agent. Otherwise, the treatment is 
mainly supportive by the use of inotropic and vasopressor agents and aggressive 
electrolyte control.  Haemodialysis, haemofiltration, extracorporeal membrane 
oxygenation (ECMO)141  and blood exchange transfusion142 have in case reports 
been described to be effective.
The mortality from PRIS is high – according to earlier reports and studies 
ranging from 64% 143 to 73%.144 Intially PRIS was assumed to only appear in the 
paediatric intensive care unit (PICU). A typical patient was  a mechanically venti-
lated child with a respiratory infection who received a high dose and a prolonged 
infusion of propofol.13,14  Currently it is believed that PRIS is more often seen in 
the adult patient who during intensive care is sedated by a normal dose of pro-
pofol. Mortality rate among reported adult cases of PRIS seem to have decreased 
over time and is now reported to be approximately 50%.145   
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Although rare, but potentially lethal, the risk for this very serious complica-
tion has prompted the American and English health authorities to ban the use of 
continuous propofol infusions for PICU sedation.146, 147 
The current recommendation by Swedish Society for Anaesthesiology and In-
tensive Care (SFAI) is that propofol-sedations longer than 24 hours and doses > 3 
mg/kg/h should be performed only in “exceptional cases”.148 
Most often PRIS have been described to occur after prolonged sedation with 
high doses. However, PRIS may not be exclusively associated with extended PICU 
or ICU sedation since there have been case reports indicating that PRIS may also 
be associated with more time limited infusions of propofol.19,145,149-152  This may 
be a concern even when using propofol in a strict paediatric anaesthesia context. 
Etomidate
Inhibition of corticosteroid synthesis during prolonged etomidate infusions: Soon 
after the clinical introduction of etomidate it became popular not only for in-
duction of anaesthesia but also for continuous ICU sedation. However, a seminal 
publication in 1983 by Ledingham indicated that prolonged infusions of etomi-
date appeared to be associated with increased mortality compared to previous 
sedation regimens.153  Soon thereafter it was shown that etomidate does interfere 
with a specific step in the synthesis of corticosteroids in the adrenal cortex.55, 154 
Due to these findings and the reports of a higher mortality rate among intensive 
patients that had received etomidate, the clinical use of the drug was substantially 
reduced. However, due to the excellent haemodynamic stability associated with 
the use of etomidate, this compound remained the drug of choice in certain cen-
tres for induction of anaesthesia and endotracheal intubation in haemodynami-
cally compromised patients as well as trauma victims.155, 156 
 A single induction dose of etomidate is generally believed not to interfere 
with corticosteroid levels in any relevant manner,157-159 although there does exist 
an on-going debate if etomidate can be safely used as an induction agent for en-
dotracheal intubation in adults with pronounced sepsis.160-164 A multicentre ran-
domized controlled trial that compared etomidate and ketamine for intubation 
in critically ill patients found no difference in mortality.159  A recently published 
meta-analysis reported data from 18 different studies (2 RCTs, 16 observational 
studies), with over 5.000 patients included.59  The major finding was that a single 
dose of etomidate did not increase mortality in patients with sepsis. 
Inhibition of corticosteroid synthesis after continuous infusion of etomidate 
has also been shown to occur in children. Murat and co-workers found clearly 
reduced levels of cortisol and aldosterone following an average infusion time of 
2.8 hours (mean total dose of etomidate 4.6 mg/kg). There was furthermore a 
prolonged rise of the precursors to cortisol and aldosterone; 11-deoxycortisol and 
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11-deoxycorticosterone.165 Although never properly studied (c.f. future perspec-
tives), a single induction dose of etomidate is most likely of no clinical relevance 
regarding cortisol levels in the vast majority of paediatric patients. In a study pub-
lished 2015 cortisol levels after a single dose propofol or etomidate were measured 
in paediatric patients undergoing urologic surgery.58 The cortisol levels, which 
were assessed by serial salivary samples, were suppressed in the etomidate group 
and lasted approximately 24 hours. However, no changes in clinical outcome were 
observed.     
In clinical practice today it is quite common to administer a dose of dexa-
methasone in order to prevent postoperative nausea and vomiting (PONV). This 
procedure is commonly regarded as totally harmless and leads to a similar sup-
pression of the hypothalamic-pituitary-adrenal axis as when etomidate is given 
as a single dose.166
Several etomidate analogues are being developed in the attempt to minimize 
the unwanted side effects of etomidate. The currently most promising is cyclopro-
pyl-methoxycarbonyl metomidate (CPMM) which in animal studies (dogs) have 
shown to maintain the favourable properties but with less adrenocortical sup-
pression compared to etomidate.167 Perhaps this drug will be an interesting alter-
native in the future.
Haemodynamic stability
Propofol
In healthy adults (ASA 1-2) the haemodynamic effects of a normal induction dose 
of propofol is usually well tolerated. However, in haemodynamically compro-
mised patients or in individuals with significant co-morbidities (ASA 3-4) propo-
fol may have very severe haemodynamic consequences.168-171
The mechanism for the decrease in blood pressure is mainly due to arterial 
vasodilatation caused by a reduced vascular sympathetic tone but is also due to a 
direct effect on myocardial contractility.172, 173
The reduction in systemic vascular resistance may be an important effect in 
children with congenital heart disease (CHD).  In children with a cyanotic car-
diac shunt the reduction in systemic vascular resistance can lead to a fall in the 
ratio of pulmonary to systemic blood flow, causing desaturation.174 It is therefore 
advisable to use propofol with great caution when anaesthetizing paediatric car-
diac patients.175
The general paediatric patient population usually does not suffer from any 
major haemodynamic side effects following the use of propofol but if used in pre-
mature or new-born babies quite dramatic hypotension may result.7, 8, 10, 176 The 
duration of such hypotension can be rather prolonged (60 min) and appears to 
outlast the anaesthetic effect of a normal bolus dose of propofol.9
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Thus, the use of propofol as an induction agent in these patient categories 
seems unwise.
Etomidate 
This drug is commonly regarded as being associated with the highest degree of 
cardiovascular stability among the anaesthesia induction agents,177 causing even 
less effects on the cardiovascular system than ketamine. For this reason etomi-
date is often selected when anesthetizing haemodynamically compromised pa-
tients, including certain paediatric patients with CHD.175, 178, 179 This group of 
patients may require anaesthesia for various procedures, non-cardiac or cardiac 
surgery and in this context etomidate is a preferred option compared to propo-
fol.175
Furthermore, etomidate is also often the preferred drug in paediatric emer-
gency departments when a rapid intubation is required.180, 181
The haemodynamic effects have so far not been properly studied in prema-
ture babies and neonates (c.f. future perspectives). However, to date there has not 
been any published data indicating that the use of etomidate in these patient cat-
egories is associated with any negative haemodynamic consequences.
More thesis-specific considerations
Pain on injection
The cause of propofol-induced injection pain is not fully understood. It has tra-
ditionally been believed to be caused by a direct stimulation of pain receptors 
and/or an indirect stimulation leading to release of different mediators causing a 
late onset of pain.27 More recent findings suggest that the TRPA1 receptor (tran-
sient receptor potential cation channel subfamily A member 1, also known as the 
“wasabi-receptor”) is a main mediator of propofol-induced injection pain. TRPA1 
resides in the cellular membrane of sensory nerve cells and is triggered by ex-
ogenous agents (e.g. wasabi or poison ivy) or by endogenous signals from tissue 
damage and inflammation.182-184
Whatever the origin; the problem is still there. Several hundreds of various 
studies have been performed and are still carried out in an attempt to diminish or 
hopefully abolish propofol injection pain. (See background) The only proven way 
to reduce the incidence and intensity of the pain is to add the local anaesthetic li-
docaine – either as a pre-treatment with venous occlusion or as an admixture.2, 3, 28
In the paediatric context injection pain is of course especially troublesome. 
It is a well-known fact that children are often frightened by needles and cannu-
las. In this setting it appears illogical to use EMLA® and various distraction tech-
niques to make the insertion of the intravenous cannula as pain-free as possible if 
you subsequently will inject “fire” into it.
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During the induction of anaesthesia it is not possible for children to adequate-
ly express their degree of pain and therefore most of the paediatric studies per-
formed have an investigator-based pain evaluation assessing parameters e.g. arm 
withdrawal, grimacing, crying or screaming. Since the paediatric studies use var-
ious methods to assess and record the incidence of pain and also have different 
study designs it is difficult to compare these studies with each other. 
Adding the local anaesthetic lidocaine to propofol reduces the injection pain 
but the need for mixing drugs is always a hazard. Apart from the time and cost 
aspects there are risks for drug mixing errors but also interactions. The addition 
of lidocaine to propofol is reported to cause a time and dose-dependent emulsion 
droplet enlargement that may cause pulmonary embolism.185, 186  Furthermore, 
mixing drugs will increase the risk for bacterial contamination, something that 
may be especially problematic regarding lipid solutions since they are prone to 
bacterial growth.187
Since some of the adverse effects are ascribed to the lipid emulsion, (e.g. hy-
perlipidaemia, allergy risks, possible bacterial growth, embolism) efforts have 
been made to find other solvents for propofol. Fospropofol disodium is a water 
soluble prodrug of propofol which was approved by the United States Food and 
Drug Administration (FDA) in 2008 and marketed as Lusedra.  No injection pain 
is reported but other adverse effects registered in a phase III trial were paraesthe-
sia (47.6%) and pruritus (14.7%).188 The onset time compared to propofol is 3-4 
longer which makes it less suitable for anaesthesia induction. Lusedra has recent-
ly been withdrawn from the US market and results from a Chinese fospropofol 
phase II trial lend further support for this. This study showed a slow onset of the 
drug and the occurrence of pruritus and or paraesthesia in 95 % of the subjects189 
which clearly makes it inferior to propofol.    
Different micro-emulsions of propofol such as Aquafol have also been devel-
oped in the attempt to eliminate adverse effects of the lipid emulsions,190, 191 but 
these drugs cause even more frequent and severe injection pain compared to tra-
ditional propofol.190 
Incidence of involuntary myoclonic movements
Many intravenous induction agents, including etomidate and propofol, may cause 
the occurrence of involuntary myoclonic activity within the first minutes follow-
ing injection. The actual mechanism responsible for this is not fully elucidated 
but is generally believed to be associated with interference with inhibitory neu-
rons in the brain stem. The phenomenon is called disinhibition – a suppression of 
cortical activity before depression of subcortical activity which leads to abnormal 
movements.45, 52, 192
Another closely related subcortical phenomenon is the nocturnal myoclonus 
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(periodic movements in sleep) that occurs in almost every healthy human as well as 
in other mammals.193
There is currently no indication that myoclonic activity is associated with any 
negative effects for the already anesthetized patient, but it may somewhat interfere 
with the assessment of anaesthetic depth and the occurrence of MM may be per-
ceived as unpleasant by the accompanying parent. Thus, despite not providing any 
added patient benefit, it may still be desirable to reduce the occurrence of myoclonic 
activity following induction of anaesthesia.
The use of etomidate appears to be associated with the highest incidence of myo-
clonic activity of the commonly used induction agents.52 The incidence of MM at in-
duction of anaesthesia in adults who have not received premedication has been re-
ported to be within the 50-80 % range.41, 45
In adults various attempts have been made to reduce the incidence of MM. Ad-
ministration of opioids, benzodiazepines and the α2-adrenoceptoragonist dexme-
detomidine prior to the injection of etomidate has been reported to reduce but not 
eliminate the occurrence of MM.41, 48, 50 Pre-treatment with magnesium sulfate194 
and lidocaine195  have also been shown to reduce the incidence and intensity of the 
myoclonic activity. To administer a small “priming” dose of etomidate a few minutes 
before the induction dose has been found effective in adults, reducing the incidence 
of MM from 75 % - 87 % (placebo) to only 26 %.45, 49
The incidence of MM was assessed as a secondary end point in Study II. In line 
with the findings in adults a considerably higher incidence of MM was observed in 
children induced with etomidate (85 %) compared to propofol (15 %).54 Thus, the in-
cidence of MM following induction of anaesthesia with etomidate does not appear to 
differ from what is observed in adults.41, 45, 49
In Study III we investigated whether the concept of using a priming dose of 
etomidate would be effective in reducing the incidence of MM also in paediatric pa-
tients. Contrary to the findings in adults we were unable to find any beneficial effect 
of a priming dose when compared to Intralipid® placebo. Why the effect of a prim-
ing dose of etomidate is not useful in children but has been found effective in adults 
is difficult to explain. However, despite using the same relative amount for the prim-
ing dose in children as in adults (10 % of the normal induction dose) it may be specu-
lated that the dose used in Study III was too small to influence the incidence of myo-
clonic movements (for further argument regarding this issue please see Discussion 
section Study III).
As an interesting post-hoc finding in Study III we could identify a specific age 
range (5-10 years of age) that appeared especially prone to the development of MM. 
The underlying reason for the higher incidence of MM in this age group is currently 
unknown. Maybe a disparity in body composition, neurologic development or phar-
macokinetics can be responsible for this observation.
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Apoptosis and long term behavioural  
and cognitive effects in animal studies
Since the ground-breaking studies by Ikonomidou et al. in 1999, followed by Jev-
tovic-Todorovic et al. in 2003, countless animal studies have been performed and 
published. A variety of research groups have documented different deleterious effects 
from anaesthetic exposure in several animal species ranging from nematodes to rhe-
sus monkeys. It is generally believed that the longer the exposure the more severe will 
the damage be. Furthermore, when several anaesthetics that act on different targets 
are combined the toxic effects seem to be intensified.90, 110 Despite these observations 
the key question remains: Is the measured cell-death found in all these preclinical 
animal studies of any clinical relevance?
If you consider the total cell number of the immature brain, anaesthetic expo-
sure will only produce a very limited enhancement of apoptotic cells compared to the 
normal on-going programmed cell death. In a report from Istaphanous et al.100  they 
found that 2 % of the cells in layer II/III of the cortical cortex expressed apoptotic 
markers after a 6 hour isoflurane anaesthetic. If extrapolated to the whole cortex this 
represents only a very small total number of cells. Brambrink et al. counted 30-40 
apoptotic cells out of 100 000 in the neonatal rhesus monkey brain after a 5 hour long 
isoflurane exposure.196 Thus, the magnitude of enhanced apoptosis is small and has 
been estimated to less than 0.1 % of the total number of cerebral neurons.197
Some of the animal studies examining cellular degeneration have also assessed 
neurocognitive outcome but here the results are conflicting. No definitive causal re-
lation between anaesthesia-induced neuroapoptosis and subsequently altered neuro-
cognitive development has yet been demonstrated. A recent animal study in fact does 
demonstrate the opposite. In an investigation by Lee et al.198 isoflurane exposure to 
new-born rats caused a huge difference in post-anaesthesia behaviour between males 
and females despite no sex differences in apoptosis.
The results from animal studies can of course not be directly translated to hu-
mans. Even when accounting for body size and different metabolic rates among spe-
cies, the doses or the duration of the exposure in animal studies tend to be high-
er than what is normally used for humans. For obvious reasons the small size of 
the neonatal rodents preclude continuous haemodynamic monitoring and repeated 
blood tests, which is standard in clinical anaesthesia for human. Therefore, some 
of the adverse effects that are attributed to the anaesthesia can be an effect of hy-
poxia, hypotension, hypocapnia or hypoglycemia. In a study by Wu et al. 14 day old 
rats were anesthetized with sevoflurane or isoflurane and were then either mechani-
cally ventilated or left spontaneously breathing.199 The spontaneous breathing rats 
had significantly higher mortality, neuroapoptosis and impaired neurocognitive out-
come compared to the mechanically ventilated rats, findings that highlight the im-
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portance of the above mentioned issues.
In animal studies the histological brain injury thought to be induced by an-
aesthetics can be assessed by histological methods, which for obvious reasons is 
not possible in children. Thus, to address the question if anaesthesia possess neu-
rotoxic effects, which may be harmful to the paediatric population, needs to be 
addressed by prospective randomized clinical trials (please see Background).               
Strengths and limitations of the dissertation studies
In Studies I-III a similar prospective, double blind, randomized controlled de-
sign, based on realistic power calculations, was used. In our mind this should be 
viewed as a considerable strength. The fact that these studies all were performed 
in a general paediatric ambulatory surgical setting, including the typical patient 
populations that represent a majority of everyday paediatric surgery, make our re-
sults easy to generalize for paediatric anaesthesia practice in general.
A certain limitation regarding Studies I-III is that the evaluation scores used 
have not undergone proper validation. In contrast to other assessment scores, it 
is not really realistic to accomplish this in the context of anaesthesia induction. 
However, we have used assessment scores that have been used in previously pub-
lished studies.26, 41, 45  (for details please see individual Studies I-III)
In Study IV a very well-established and robust animal model was used that 
should be considered to be advantageous. To investigate potential apoptosis in 
larger parts of the brain did appear more relevant to us than focusing on small 
and exceptionally vulnerable areas that probably do not have any effects on long-
term outcome. Furthermore, to expose the mice at PND 10 does much better 
translate to exposure in human early infancy when the majority of major surgi-
cal interventions for birth defects and malformations are performed. On the con-
trary, exposure at PND 7 which has been the norm in a large part of the published 
literature is equal to an extremely premature human baby and, does not mirror 
the correct time for major neonatal surgery in human babies.83, 200
One limitation regarding study IV is that some proteins, such as caspases, 
are expressed only transiently. The time from initiation of apoptosis to comple-
tion can occur as quickly as 2–3 hours. Therefore a false negative result can occur 
if the assay is done too early or too late. It is then reassuring that the behavioural 
testing did not show any difference between the etomidate-exposed group and 
the control group. 
As is the case with all studies within this field that has been performed in neo-
natal rodents, there are a number of limitations that should be recognised, e.g. 
species differences, dosage issues, and lack of proper monitoring of physiologic 
parameters. For a more detailed discussion relating to this, please see the Discus-
sion section of Study IV.
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Future perspectives/Further studies
The current thesis indicates that etomidate is a valid alternative for intravenous 
induction of anaesthesia in the paediatric population. Although etomidate can be 
used in clinical practice without any major hesitation there are still a number of 
issues that need to be clarified.
First, the effect of a single induction dose of etomidate on corticosteroid syn-
thesis needs to be further elucidated. Initially the effect in healthy children (ASA 
1-2) should be investigated followed by studies performed in sicker patients, e.g. 
ASA 3-4 individuals, trauma victims and septic paediatric patients. If any clini-
cally relevant suppression of cortisol synthesis should emerge in the more vulner-
able patient population it may be recommended to follow plasma cortisol after the 
use of etomidate. If low cortisol levels is detected it can be treated with relevant 
substitution by i.v. cortisone.
Second, to hopefully verify that etomidate is associated with better haemody-
namic stability compared to propofol also in the vulnerable group of premature 
babies. This would be welcomed since cardiovascular instability in these patients 
will affect morbidity, e.g. the incidence of intraventricular haemorrhage and leu-
komalacia.201
Third, further studies of interventions that may reduce the incidence of myo-
clonic movements are warranted.
The current debate questions the overall validity of animal studies regarding 
potential neurotoxicity of exposure to anaesthetics in early life.200, 202, 203 How-
ever, further animal studies are needed to identify various approaches that may 
ameliorate or even inhibit the negative effects that have been shown for most an-
aesthetics. The use of alpha-2 adrenoceptor agonists has been identified as one 
possibility in this regard112, 204 but the study of other possible therapeutic options 
would be much welcomed. Also, the further development of new alternatives to 
the currently available agents, e.g. the etomidate analogue CPMM which seem to 
lack the negative effect on the steroid synthesis is another option.167
All in all, we believe that etomidate can establish itself as a useful alternative 
for intravenous induction of anaesthesia in children.
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7 Conclusions
From the studies of which this thesis consists the following conclusions are drawn.
Study I
A new MCT-LCT propofol formulation as a plain solution is associated with a 
higher incidence of injection pain compared to LCT propofol with added lido-
caine when used for induction of anaesthesia in children.
Study II
The use of a new lipid formulation of etomidate is associated with significantly 
less injection pain than propofol with added lidocaine when used for induction of 
anaesthesia in children.
Study III
The use of a small, non-sedative, priming dose does not influence the incidence of 
involuntary myoclonic movements after i.v. induction of anaesthesia with etomi-
date in children.
Children in the age range of 5–10 years appear to be more prone to react with 
involuntary myoclonic movements after i.v. induction of anaesthesia with etomi-
date than other paediatric age groups.
Study IV 
A single dose of etomidate in early infant mice at PND 10 does not produce evi-
dence of enhanced cerebral apoptosis or impaired adult motor behaviour.
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